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PHeart Rhythm Disorders
Prognostic Importance of Atrial Fibrillation
in Implantable Cardioverter-Defibrillator Patients
C. Jan Willem Borleffs, MD, Johannes B. van Rees, MD, Guido H. van Welsenes, MS,
Enno T. van der Velde, PHD, Lieselot van Erven, MD, PHD, Jeroen J. Bax, MD, PHD,
Martin J. Schalij, MD, PHD
Leiden, the Netherlands
Objectives This study aimed to assess the prevalence of different types of atrial fibrillation (AF) and their prognostic impor-
tance in implantable cardioverter-defibrillator (ICD) patients.
Background The prevalence of AF has taken epidemic proportions in the population with cardiovascular disease. The prog-
nostic importance of different types of AF in ICD patients remains unclear.
Methods Data on 913 consecutive patients (79% men, mean age 62  13 years) receiving an ICD at the Leiden Univer-
sity Medical Center were prospectively collected. Among other characteristics, the existence and type of AF (par-
oxysmal, persistent, or permanent) were assessed at implantation. During follow-up, the occurrence of appropri-
ate or inappropriate device therapy as well as mortality was noted.
Results At implantation, 73% of patients had no history of AF, 9% had a history of paroxysmal AF, 7% had a history of
persistent AF, and 11% had permanent AF. During 833  394 days of follow-up, 117 (13%) patients died, 228
(25%) patients experienced appropriate device discharge, and 139 (15%) patients received inappropriate
shocks. Patients with permanent AF exhibited more than double the risk of mortality, ventricular arrhythmias
triggering device discharge, and inappropriate device therapy. Patients with paroxysmal or persistent AF did not
show a significant increased risk of mortality or appropriate device therapy but demonstrated almost 3 times
the risk of inappropriate device therapy.
Conclusions In the population currently receiving ICD treatment outside the setting of clinical trials, a large portion has either
a history of AF or permanent AF. Both types of AF have prognostic implications for mortality and appropriate as
well as inappropriate device discharge. (J Am Coll Cardiol 2010;55:879–85) © 2010 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.053o
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mplantable cardioverter-defibrillator (ICD) therapy, ini-
ially in survivors of life-threatening arrhythmias (1–3), but
lso more recently in the primary prevention of sudden
rrhythmic death in selected ischemic and nonischemic
atients at high risk, based solely on a poor left ventricular
jection fraction (LVEF) (4–7). The implementations of
hese results in the international guidelines have caused, in
ddition to a considerable increase in the number of
mplants, a significant change in the population considered
or ICD therapy because the majority of implantations now
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ccepted September 21, 2009.ccurs in patients with a low LVEF and symptoms of heart
ailure (primary prevention patients) (8).
Atrial fibrillation (AF) is common in patients with low
VEF and symptoms of heart failure, with a reported
revalence of AF in congestive heart failure patients of as
igh as 50% in patients with New York Heart Association
NYHA) functional class IV (9–12). Furthermore, AF is
ssociated with significant morbidity and mortality, both in
he general population and more specifically in patients with
eart failure (13,14).
As the number of ICD implants in patients with a low
VEF and heart failure is increasing, it can be expected that
ore patients with paroxysmal, persistent, or permanent AF
ill receive an ICD. So far, most studies have focused on a
ingle type of AF (e.g., paroxysmal/persistent or permanent
F) and were often conducted in the setting of a clinical
rial (15–19). The prevalence and prognostic implications of
history of AF at ICD implantation remain unclear. The
resent study aims to provide insight into the effects of AF on
S
L
o
w
b
l
i
r
w
A
o
w
2
e
a
p
d
y
e
c
s
c
D
i
t
t
f
(
B
G
V
L
e
c
(
c
v
i
t
F
b
p
p
S
S
c
w
u
w
c
C
d
d
T
a
p
w
r
c
w
R
B
r
w
l
i
8
y
c
c
b
o
7
o
A
r
p
i
s
h
N
d
M
1
r
8
3
a
o
880 Borleffs et al. JACC Vol. 55, No. 9, 2010
Atrial Fibrillation in ICD Patients March 2, 2010:879–85mortality, the occurrence of ven-
tricular arrhythmias, and inappro-
priate device therapy during long-
term follow-up in a large cohort of
ICD patients.
Methods
Patients and study protocol.
Since 1996, all patients receiving
an ICD at the Leiden University
Medical Center were prospec-
tively collected in the depart-
mental Cardiology Information
ystem (EPD-Vision, Leiden University Medical Center,
eiden, the Netherlands). Characteristics at baseline, data
f the implant procedure, and data for all follow-up visits
ere recorded.
Eligibility for ICD implantation in this population was
ased on international guidelines that, due to evolving guide-
ines, might have changed over time. Patients underwent ICD
mplantation after surviving life-threatening ventricular ar-
hythmias or in the presence of a depressed LVEF with or
ithout nonsustained ventricular tachycardia (8,20).
F. At baseline, patients were grouped according to the type
f AF. This resulted in the following 4 groups: 1) patients
ithout a history of (documented) AF, the no AF group;
) patients with a history of paroxysmal AF as documented by
lectrocardiography; 3) patients with a history of persistent AF
s documented on electrocardiography; and 4) patients with
ermanent, accepted AF.
If the arrhythmia terminated spontaneously and within 7
ays, AF was designated paroxysmal; when sustained be-
ond 7 days or being terminated by pharmacological or
lectrical cardioversion, AF was termed persistent. The
ategory of persistent AF also includes cases of long-
tanding AF, usually leading to permanent AF, in which
ardioversion has failed or has been foregone (10,21).
evice implantation. All defibrillator systems used were
mplanted transvenously and without thoracotomy. During
he implantation procedure, testing of sensing and pacing
hresholds and defibrillation threshold testing was per-
ormed. The systems used were manufactured by Biotronik
Berlin, Germany), Medtronic (Minneapolis, Minnesota),
oston Scientific (Natick, Massachusetts) (formerly CPI,
uidant, St. Paul, Minnesota), and St. Jude Medical/
entritex (St. Paul, Minnesota).
ong-term follow-up. Patient check-ups were scheduled
very 3 to 6 months. Device interrogation printouts were
hecked for appropriate and inappropriate ICD therapy
antitachycardia pacing [ATP] or shocks). Therapies were
lassified as appropriate when they occurred in response to
entricular tachycardia or ventricular fibrillation and as
nappropriate when triggered by sinus or supraventricular
achycardia, T-wave oversensing, or electrode dysfunction.
Abbreviations
and Acronyms
AF  atrial fibrillation
ATP  antitachycardia
pacing
CI  confidence interval
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Associationurthermore, follow-up included all-cause mortality. tIn the Dutch health care system, all patients are followed
y the implantation center. Because periodic follow-up was
erformed every 3 to 6 months, patients without data for the
ast 6 months were considered lost to follow-up.
tatistical analysis. Continuous data are expressed as mean 
D; dichotomous data are presented as numbers and per-
entages. Comparison of continuous or dichotomous data
as performed with the Student t test for paired and
npaired data and chi-square tests with Yates correction
hen appropriate. Nonparametric data (NYHA functional
lass) were compared using the Mann-Whitney U test.
umulative event rates (all-cause mortality, appropriate
evice therapy, appropriate device shocks, and inappropriate
evice shocks) were analyzed by the Kaplan-Meier method.
he relationship between different types of AF at baseline
nd the occurrence of end points was assessed using a Cox
roportional hazard model, calculating a hazard ratio (HR)
ith a 95% confidence interval (CI) and adjusting for age, sex,
enal clearance, LVEF, QRS duration, NYHA functional
lass, and use of beta-blockers. For all tests, a p value 0.05
as considered significant.
esults
aseline characteristics. Data for 955 consecutive patients
eceiving an ICD in the Leiden University Medical Center
ere prospectively collected. Forty-two (4.4%) patients were
ost to follow-up. The remaining 913 ICD recipients were
ncluded in the analysis. The mean follow-up time was
33  394 days.
The majority of patients (79% men, mean age 62  13
ears) had a depressed LVEF (32  14%), wide QRS
omplex (127  35 ms), and poor renal function (renal
learance 83  38 ml/min). Medications included beta-
lockers in 76%, angiotensin-converting enzyme inhibitors
r AT antagonists in 82%, and diuretics for heart failure in
0%. Baseline characteristics are summarized in Table 1.
A total of 663 (73%) out of all 913 patients had no history
f AF (no AF), 84 (9%) patients had a history of paroxysmal
F, 64 (7%) patients had a history of persistent AF, and the
emaining 102 (11%) patients had permanent AF. All
atients with a history of paroxysmal or persistent AF were
n sinus rhythm at discharge after device implantation. As is
hown in Table 1, when compared with patients without a
istory of AF, patients with AF were older, had higher
YHA functional class, and were more often treated with
iuretics, amiodarone, and oral anticoagulants.
ortality. During a mean follow-up of 833  394 days,
17 (13%) patients died. The study population mortality
ates were 5% (95% CI: 4% to 7%) at 1 year, 11% (95% CI:
% to 13%) at 2 years, and 15% (95% CI: 12% to 17%) at
years of follow-up. Comparing the 4 groups, survival
nalysis showed a 3-year cumulative event rate for mortality
f 12% (95% CI: 9% to 15%) for no AF, 15% (95% CI: 8%
o 24%) for paroxysmal AF, 17% (95% CI: 7% to 27%) for
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March 2, 2010:879–85 Atrial Fibrillation in ICD Patientsersistent AF, and 32% (95% CI: 20% to 43%) for perma-
ent AF (Fig. 1).
Of interest, patients with paroxysmal AF or persistent AF
id not demonstrate a significant higher risk of mortality.
owever, patients with permanent AF exhibited a 70%
ncreased risk of mortality (adjusted HR: 1.7, 95% CI: 1.0 to
.7, p  0.033).
ppropriate device therapy. During follow-up, ventricular
rrhythmias causing appropriate device therapy (ATP or
hock) were observed in 228 (25%) patients. A total of 5,116
pisodes were noted, consisting of 4,793 (range 1 to 2,194)
pisodes terminated with ATP in 166 patients and 304
range 1 to 33) episodes terminated by ICD shock in 112
atients.
The cumulative event rates for appropriate device therapy
ATP or shock) were 15% (95% CI: 13% to 18%) at 1 year,
4% (95% CI: 21% to 27%) at 2 years, and 30% (95% CI:
Baseline CharacteristicsTable 1 Baseline Characteristics
Clinical Parameters
All
(n  913)
No A
(n  6
Male sex 722 (79%) 515 (7
Age (yrs) 62 13 61
Secondary prevention 140 (15%) 94 (1
History of VT 93 (66%) 62 (6
History of VF 47 (34%) 32 (3
Primary prevention 773 (85%) 569 (8
History of nsVT 201 (26%) 150 (2
Ischemic heart disease 561 (61%) 423 (6
NYHA functional class
I 228 (25%) 188 (2
II 346 (38%) 253 (3
III 320 (35%) 208 (3
IV 19 (2%) 14 (2
Renal clearance (ml/min) 83 38 86
QRS duration (ms) 127 35 125
LVEF (%) 32 14 33
Diabetes 177 (19%) 127 (1
History of smoking 380 (42%) 287 (4
Body mass index (kg/m2) 26 4 26
Device type
Single-chamber 43 (5%) 20 (3
Dual-chamber 409 (45%) 234 (4
CRT-D 461 (51%) 319 (4
Medication
Beta-blockers 691 (76%) 510 (7
ACE inhibitors/AT antagonist 750 (82%) 548 (8
Calcium antagonists 64 (7%) 52 (8
Diuretics 641 (70%) 440 (6
Statins 594 (65%) 445 (6
Amiodarone 125 (14%) 68 (1
Aspirin 364 (40%) 300 (4
Oral anticoagulants 504 (55%) 316 (4
*p  0.01; †p  0.05; ‡p  0.001; all compared with no AF group. §
ACE angiotensin-converting enzyme; AF atrial fibrillation; AT
left ventricular ejection fraction; nsVT  nonsustained ventricular tac
VT  ventricular tachycardia.4% to 34%) at 3 years of follow-up. wAs shown in Figure 2, the 3-year cumulative event
ates for appropriate device therapy were 29% (95% CI:
4% to 33%) for no AF, 26% (95% CI: 14% to 39%) for
aroxysmal AF, 26% (95% CI: 13% to 38%) for persistent
F, and 49% (95% CI: 36% to 61%) for permanent AF.
atients with permanent AF exhibited twice the risk of
ppropriate therapy compared with patients without a
istory of AF (adjusted HR: 2.2, 95% CI: 1.6 to 3.2, p 
.001). The no AF group demonstrated event rates similar to
hose of patients with a history of paroxysmal or persis-
ent AF.
As shown in Figure 3 and Table 2, the occurrence of
ppropriate shocks alone showed a distribution similar to that
f the occurrence of all appropriate therapy among the 4
roups. No differences were observed between patients without
history of AF and those with a history of paroxysmal or
ersistent AF. Moreover, a doubled risk of appropriate shocks
Paroxysmal AF
(n  84)
Persistent AF
(n  64)
Permanent AF
(n  102)
64 (76%) 53 (83%) 90 (88%)*
64 11† 66 10* 67 10‡
22 (26%)* 9 (14%) 15 (15%)
15 (68%) 7 (78%) 9 (60%)
7 (32%) 2 (22%)§ 6 (40%)
62 (74%)* 55 (86%) 87 (85%)
17 (27%) 15 (27%) 19 (22%)
49 (58%) 39 (61%) 50 (49%)*
17 (20%) 10 (16%)† 13 (13%)‡
37 (44%) 24 (38%) 32 (31%)
28 (33%) 30 (47%)† 54 (53%)‡
2 (2%)§ 0 (0%)§ 3 (3%)§
75 39* 77 43 72 29‡
123 33 129 35 140 34‡
32 15 32 14 30 12
16 (19%) 14 (22%) 20 (20%)
36 (43%) 24 (38%) 33 (32%)†
26 4 26 4 26 4
4 (5%)§ 2 (3%)§ 17 (17%)‡§
39 (46%) 26 (41%) 20 (20%)
41 (49%) 36 (56%) 65 (64%)*
63 (75%) 46 (72%) 72 (71%)
66 (79%) 49 (77%) 87 (85%)
3 (4%) 3 (5%)§ 6 (6%)
65 (77%)† 47 (73%) 89 (87%)‡
53 (63%) 44 (69%) 52 (51%)‡
19 (23%)‡ 15 (23%)* 23 (23%)‡
32 (38%) 22 (34%) 10 (10%)‡
51 (61%)† 42 (66%)* 95 (93%)‡
rison was performed with Yates correction.
nsin; CRT-D cardiac resynchronization therapy-defibrillator; LVEF
a; NYHA  New York Heart Association; VF  ventricular fibrillation;F
63)
8%)
13
4%)
6%)
4%)
6%)
6%)
4%)
8%)
8%)
1%)
%)
38
34
14
9%)
3%)
4
%)
9%)
8%)
7%)
3%)
%)
6%)
7%)
0%)
5%)
8%)
Compa
angioteas observed in the permanent AF group compared with
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Atrial Fibrillation in ICD Patients March 2, 2010:879–85atients with no history of AF (adjusted HR: 2.4, 95% CI: 1.5
o 4.0, p  0.001).
nappropriate device shocks. A total of 139 (15%) pa-
ients experienced at least 1 inappropriate device discharge.
hen comparing the 4 groups, major differences in event
ates were observed. Three-year event rates for inappropri-
te shocks were 13% (95% CI: 10% to 17%) for no AF, 28%
95% CI: 15% to 40%) for paroxysmal AF, 18% (95% CI:
5% to 41%) for persistent AF, and 32% (95% CI: 19% to
5%) for permanent AF (Fig. 4). Compared with the no AF
roup, the permanent AF group showed more than double
he risk of the inappropriate shocks (adjusted HR: 2.7, 95%
Figure 1 All-Cause Mortality
Kaplan-Meier curve for all-cause mortality in patients without a history of
atrial fibrillation (AF) (no AF, black line), paroxysmal AF (green line), persistent
AF (orange line), or permanent AF (red line).
Figure 2 Appropriate Device Therapy
Kaplan-Meier curve for the occurrence of first appropriate device therapy in
patients without a history of atrial fibrillation (AF) (no AF, black line), paroxys-
mal AF (green line), persistent AF (orange line), or permanent AF (red line).tI: 1.7 to 4.4, p  0.001). Patients with a history of
aroxysmal AF had the highest risk of inappropriate device
hocks (adjusted HR: 2.9, 95% CI: 1.7 to 4.8, p  0.001)
uring follow-up. It is of note that in the no AF group,
ew-onset AF during follow-up was the cause of inappro-
riate device shocks in 27 (4%) patients.
iscussion
he main findings of the current study on the prognostic
mportance of AF in ICD patients can be summarized as
ollows: 1) in the population currently receiving ICD
reatment, 9% have a history of paroxysmal AF, 7% have a
istory of persistent AF, and 11% have permanent AF;
) patients with permanent AF exhibited more than double
he risk of mortality, ventricular arrhythmias triggering
evice discharge, and inappropriate device shocks than
atients without AF; and 3) patients with a history of
aroxysmal or persistent AF did not show a significantly
ncreased risk of mortality or appropriate device therapy but
emonstrated almost triple the risk of inappropriate device
hocks.
The present analysis adds to the previous literature in that
t distinguishes between different types of AF and assesses
he population currently considered for ICD treatment
utside the setting of clinical trial.
ortality. Previous trials demonstrated the importance of
F in the general population as well as in a population with
ymptomatic or asymptomatic heart failure (13,14).
enjamin et al. (13) showed that the occurrence of AF was
ssociated with a 1.5- to 1.9-fold risk of all-cause mortality,
ven after adjustment for further cardiovascular conditions
elated to AF. These findings seem comparable to the 1.7
Figure 3 Appropriate Device Shock
Kaplan-Meier curve for the occurrence of first appropriate shock in patients
without a history of atrial fibrillation (AF) (no AF, black line), paroxysmal AF
(green line), persistent AF (orange line), or permanent AF (red line).imes increased risk of mortality in patients with permanent
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March 2, 2010:879–85 Atrial Fibrillation in ICD PatientsF, as observed in the current analysis. However, when
pecifically assessing a population with symptoms of heart
ailure, findings in current literature are inconsistent regard-
ng the potential relationship between AF and the risk of
ortality (14,22–25). In a post hoc analysis of the MADIT
I (Multicenter Automatic Defibrillator Implantation
rial), Zareba et al. (7,19) compared patients with sinus
hythm and those with AF. Because AF was defined by its
resence on the electrocardiogram at enrollment, one might
ssume that all the patients identified with AF have perma-
ent AF and those with paroxysmal or persistent AF, if not
oincidentally present at enrollment, will have been classi-
ed as having sinus rhythm. Furthermore, the trial only
ncluded primary prevention ICD recipients with a previous
yocardial infarction. In contrast to the current study,
areba et al. (19) did not find a relationship between AF
nd mortality after adjustment for other variables.
ppropriate ICD therapy. One might hypothesize that
he occurrence of any type of AF is a marker for worse
eneral cardiac status and therefore that AF will be posi-
ively correlated with the occurrence of ventricular arrhyth-
ias. On the other hand, AF could initiate episodes of
entricular arrhythmias and might therefore directly influ-
nce the occurrence of ventricular arrhythmias and conse-
uent appropriate device therapy. The facilitation of AF in
he initiation of ventricular tachyarrhythmias was observed
y Roy et al. (26) during an electrophysiological study.
ater, Stein et al. (27) observed that 8.9% of the episodes of
entricular arrhythmia were accompanied by AF. Earlier
tudies suggested that ventricular arrhythmias are evoked by
apid and uncontrolled atrioventricular conduction (28–30).
ore recently, Grönefeld et al. (16) suggested that the
trioventricular nodal conduction pattern preceding ventric-
Figure 4 Inappropriate Device Shock
Kaplan-Meier curve for the occurrence of first inappropriate device shock in
patients without a history of atrial fibrillation (AF) (no AF, black line), paroxys-
mal AF (green line), persistent AF (orange line), or permanent AF (red line).ular tachyarrhythmia were short-long-short sequencesEv
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Atrial Fibrillation in ICD Patients March 2, 2010:879–85ather than solely a rapid conduction. The irregular ventric-
lar excitation leads to heterogeneous depolarization that
ubsequently renders the myocardium more susceptible to
entricular arrhythmias (31,32). In line with the current
ndings, previous studies confirm AF to have a positive
orrelation with the occurrence of ventricular arrhythmias
16–18). Interestingly, a post hoc analysis of the MADIT II
rial did not demonstrate a difference in the occurrence of
ppropriate therapy when comparing (mostly permanent)
F with patients in sinus rhythm (19). A possible explana-
ion for this difference could be that the permanent AF
roup in the current study is sicker in a manner not
ompletely accounted for by post hoc statistical adjustment.
he present study did not show an increase in appropriate
evice therapy in the groups with a history of paroxysmal or
ersistent AF, which could imply that these patients do not
ave a deterioration of their general cardiac status of such
agnitude to consequently cause a higher occurrence of
entricular arrhythmia. Thus far, no analysis had been
eported of the prognostic implications of the different types
f AF.
nappropriate ICD shocks. Previous studies have dem-
nstrated the relationship between the existence of AF
nd inappropriate device discharge and the consequent
egative effect of inappropriate device discharge on pa-
ient quality of life (33–35). Furthermore, recent research
as demonstrated the impact of inappropriate shock
elivery on mortality (33,36). These findings stress the
mportance of clear identification of patients at high risk
f inappropriate shocks to better inform patients and to
ptimize individual patient treatment. The current study
aps the importance of different types of AF on the
ccurrence of inappropriate shocks and highlights the
igh event rate in patients with persistent, permanent,
nd, most importantly, paroxysmal AF. A potential
xplanation of the higher event rate in the paroxysmal AF
roup, even when compared with the group with perma-
ent AF, can be explained by the fact that clinicians will
ore often adjust their treatment (such as atrioventricu-
ar node ablation) if AF is ongoing. Additionally, the
igher occurrence of ventricular arrhythmias in the group
ith permanent AF might cause a more aggressive
harmacological antiarrhythmic treatment.
tudy limitations. This was a nonrandomized, prospec-
ive, observational cohort study performed to assess the
ong-term follow-up in ICD patients outside the setting of
clinical trial. Because patients were collected over a 4-year
eriod, expanding guidelines for the implantation of ICDs,
reatment of acute myocardial infarction, and pharmacolog-
cal antiarrhythmic therapy could have created an heteroge-
eous population. Furthermore, standard ICD settings at
ischarge could have been altered during follow-up. Finally,
pplying a different classification of AF might have altered
he results.onclusions
n the population currently receiving ICD treatment outside
he setting of a clinical trial, 11% has permanent AF and
6% has a history of paroxysmal or persistent AF. The
xistence of permanent AF doubles the risk of mortality and
ppropriate as well as inappropriate device therapy. Parox-
smal and persistent AF did not prove to have an effect on
ortality or the occurrence of appropriate device discharge.
owever, the rate of inappropriate shocks is significantly
ncreased in this group.
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